TABLE OF CONTENTS
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF THE NORTH AMERICA HIGH CONTENT SCREENING MARKET 19
1.4 LIMITATIONS 21
1.5 MARKETS COVERED 21
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 CURRENCY AND PRICING 27
2.5 DBMR TRIPOD DATA VALIDATION MODEL 28
2.6 MULTIVARIATE MODELLING 31
2.7 PRODUCT TYPE LIFELINE CURVE 31
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.9 DBMR MARKET POSITION GRID 33
2.10 MARKET APPLICATION COVERAGE GRID 34
2.11 VENDOR SHARE ANALYSIS 35
2.12 SECONDARY SOURCES 36
2.13 ASSUMPTIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 39
4.1 PESTEL ANALYSIS 40
4.2 PORTER'S FIVE FORCES MODEL 41
5 NORTH AMERICA HIGH CONTENT SCREENING MARKET: REGULATIONS 42
6 MARKET OVERVIEW, NORTH AMERICA HIGH CONTENT SCREENING MARKET 44
6.1 DRIVERS 46
6.1.1 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH CONTENT SCREENING 46
6.1.2 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 46
6.1.3 INCREASING RESEARCH ACTIVITIES ASSOCIATED WITH THE USAGE OF HIGH CONTENT SCREENING 47
6.1.4 INCREASING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 48
6.2 RESTRAINTS 48
6.2.1 HIGH COST ASSOCIATED WITH INITIAL SETUP AND MAINTENANCE 48
6.2.2 COMPLEXITY ASSOCIATED WITH CELLULAR AND MOLECULAR SAMPLES 49
6.3 OPPORTUNITIES 50
6.3.1 GROWING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS) PROVIDING HCS SERVICES 50
6.3.2 RISING INTEGRATION WITH ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DISCOVERY AND DEVELOPMENT 50
6.3.3 INCREASING GOVERNMENT INITIATIVE AND FUNDING IN R&D 51
6.4 CHALLENGES 51
6.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS TO OPERATE HCS 51
6.4.2 DATA SECURITY AND DATA MANAGEMENT PROBLEMS IN HCS 52
7 NORTH AMERICA HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE 53
7.1 OVERVIEW 54
7.2 INSTRUMENTS 57
7.2.1 CELL IMAGING AND ANALYSIS SYSTEM 58
7.2.1.1 FIXED 58
7.2.1.2 MOBILE 58
7.2.2 HIGH-CONTENT AND SCREENING SYSTEM 58
7.2.2.1 FIXED 59
7.2.2.2 MOBILE 59
7.2.3 FLOW CYTOMETRY 59
7.2.4 INVITROGEN HCA ONSTAGE INCUBATOR 59
7.2.5 MICROPLATE MOVER 59
7.2.6 OTHERS 59
7.3 SOFTWARE 59
7.4 CONSUMABLES 60
7.4.1 REAGENTS & ASSAY KITS 61
7.4.2 MICROPLATES 61
7.4.3 OTHERS 61
7.5 ACCESSORIES 61
7.6 SERVICES 62
8 NORTH AMERICA HIGH CONTENT SCREENING MARKET, BY APPLICATION 64
8.1 OVERVIEW 65
8.2 PRIMARY AND SECONDARY SCREENING 68
8.2.1 INSTRUMENTS 69
8.2.2 CONSUMABLES 69
8.2.3 ACCESSORIES 69
8.2.4 SERVICES 69
8.3 TARGET IDENTIFICATION AND VALIDATION 69
8.3.1 INSTRUMENTS 70
8.3.2 CONSUMABLES 70
8.3.3 ACCESSORIES 70
8.3.4 SERVICES 71
8.4 TOXICITY STUDIES 71
8.4.1 INSTRUMENTS 72
8.4.2 CONSUMABLES 72
8.4.3 ACCESSORIES 72
8.4.4 SERVICES 72
8.5 COMPOUND PROFILING 72
8.5.1 INSTRUMENTS 73
8.5.2 CONSUMABLES 73
8.5.3 ACCESSORIES 73
8.5.4 SERVICES 74
8.6 OTHER APPLICATIONS 74
9 NORTH AMERICA HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY 75
9.1 OVERVIEW 76
9.2 MICROSCOPY 79
9.3 FLOW CYTOMETRY 79
9.4 IMMUNOHISTOCHEMISTRY 80
9.5 MASS SPECTROMETRY 81
9.6 ELISA 82
9.7 WESTERN BLOTTING 83
9.8 OTHERS 83
9.8.1 3D CELL CULTURE MODEL 84
9.8.1.1 STEROIDS 85
9.8.1.2 ORGANOIDS 85
9.8.1.3 TISSUE ON A CHIP 85
9.8.2 EXTRACELLULAR MATRIX BASED SCAFFOLD 85
9.8.3 SYNTHETIC HYDROGEL AND SCAFFOLD 85
10 NORTH AMERICA HIGH CONTENT SCREENING MARKET, BY END USER 86
10.1 OVERVIEW 87
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 90
10.2.1 INSTRUMENTS 90
10.2.2 CONSUMABLES 91
10.2.3 ACCESSORIES 91
10.2.4 SERVICES 91
10.3 CONTRACT RESEARCH ORGANIZATIONS 91
10.3.1 INSTRUMENTS 92
10.3.2 CONSUMABLES 92
10.3.3 ACCESSORIES 92
10.3.4 SERVICES 92
10.4 LABORATORIES 93
10.4.1 INSTRUMENTS 94
10.4.2 CONSUMABLES 94
10.4.3 ACCESSORIES 94
10.4.4 SERVICES 94
10.5 ACADEMIC AND GOVERNMENT INSTITUTES 94
10.5.1 INSTRUMENTS 95
10.5.2 CONSUMABLES 95
10.5.3 ACCESSORIES 95
10.5.4 SERVICES 95
10.6 OTHERS 96
11 NORTH AMERICA HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL 97
11.1 OVERVIEW 98
11.2 DIRECT TENDERS 101
11.3 RETAIL SALES 101
12 NORTH AMERICA HIGH CONTENT SCREENING MARKET, BY REGION 103
12.1 NORTH AMERICA 104
12.1.1 U.S. 115
12.1.2 CANADA 122
12.1.3 MEXICO 129
13 NORTH AMERICA HIGH CONTENT SCREENING MARKET, COMPANY LANDSCAPE 136
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 136
14 NORTH AMERICA CONTENT SCREENING MARKET, COMPANY PROFILES 137
14.1 THERMO FISHER SCIENTIFIC INC. (2022) 137
14.1.1 COMPANY SNAPSHOT 137
14.1.2 REVENUE ANALYSIS 137
14.1.3 COMPANY SHARE ANALYSIS 138
14.1.4 PRODUCT PORTFOLIO 138
14.1.5 RECENT DEVELOPMENT 138
14.2 BD 139
14.2.1 COMPANY SNAPSHOT 139
14.2.2 REVENUE ANALYSIS 139
14.2.3 COMPANY SHARE ANALYSIS 140
14.2.4 PRODUCT PORTFOLIO 140
14.2.5 RECENT DEVELOPMENTS 140
14.3 PERKINELMER INC. (2022) 141
14.3.1 COMPANY SNAPSHOT 141
14.3.2 REVENUE ANALYSIS 141
14.3.3 COMPANY SHARE ANALYSIS 142
14.3.4 PRODUCT PORTFOLIO 142
14.3.5 RECENT DEVELOPMENTS 143
14.4 YOKOGAWA ELECTRIC CORPORATION (2022) 144
14.4.1 COMPANY SNAPSHOT 144
14.4.2 REVENUE ANALYSIS 144
14.4.3 COMPANY SHARE ANALYSIS 145
14.4.4 PRODUCT PORTFOLIO 145
14.4.5 RECENT DEVELOPMENT 145
14.5 MOLECULAR DEVICES, LLC. (A SUBSIDIARY OF DANAHER CORPORATION) 146
14.5.1 COMPANY SNAPSHOT 146
14.5.2 REVENUE ANALYSIS 146
14.5.3 COMPANY SHARE ANALYSIS 147
14.5.4 PRODUCT PORTFOLIO 147
14.5.5 RECENT DEVELOPMENT 148
14.6 AGILENT TECHNOLOGIES, INC. (2022) 149
14.6.1 COMPANY SNAPSHOT 149
14.6.2 REVENUE ANALYSIS 149
14.6.3 PRODUCT PORTFOLIO 150
14.6.4 RECENT DEVELOPMENT 150
14.7 ALIGNED GENETICS, INC. (2022) 151
14.7.1 COMPANY SNAPSHOT 151
14.7.2 REVENUE ANALYSIS 151
14.7.3 PRODUCT PORTFOLIO 152
14.7.4 RECENT DEVELOPMENT 152
14.8 ARACELI BIOSCIENCES 153
14.8.1 COMPANY SNAPSHOT 153
14.8.2 PRODUCT PORTFOLIO 153
14.8.3 RECENT DEVELOPMENT 153
14.9 AXXAM S.P.A 154
14.9.1 COMPANY SNAPSHOT 154
14.9.2 PRODUCT PORTFOLIO 154
14.9.3 RECENT DEVELOPMENT 154
14.10 BIO-RAD LABORATORIES, INC. (2022) 155
14.10.1 COMPANY SNAPSHOT 155
14.10.2 REVENUE ANALYSIS 155
14.10.3 PRODUCT PORTFOLIO 156
14.10.4 RECENT DEVELOPMENTS 156
14.11 CARL ZEISS AG 157
14.11.1 COMPANY SNAPSHOT 157
14.11.2 REVENUE ANALYSIS 157
14.11.3 PRODUCT PORTFOLIO 158
14.11.4 RECENT DEVELOPMENT 158
14.12 CORNING INCORPORATED 159
14.12.1 COMPANY SNAPSHOT 159
14.12.2 REVENUE ANALYSIS 159
14.12.3 PRODUCT PORTFOLIO 160
14.12.4 RECENT DEVELOPMENT 160
14.13 DE NOVO SOFTWARE 161
14.13.1 COMPANY SNAPSHOT 161
14.13.2 PRODUCT PORTFOLIO 161
14.13.3 RECENT DEVELOPMENTS 161
14.14 EVIDENT 162
14.14.1 COMPANY SNAPSHOT 162
14.14.2 PRODUCT PORTFOLIO 162
14.14.3 RECENT DEVELOPMENT 162
14.15 GENEDATA AG 163
14.15.1 COMPANY SNAPSHOT 163
14.15.2 PRODUCT PORTFOLIO 163
14.15.3 RECENT DEVELOPMENT 163
14.16 MERCK KGAA 164
14.16.1 COMPANY SNAPSHOT 164
14.16.2 REVENUE ANALYSIS 164
14.16.3 PRODUCT PORTFOLIO 165
14.16.4 RECENT DEVELOPMENTS 165
14.17 MILTENYI BIOTEC 166
14.17.1 COMPANY SNAPSHOT 166
14.17.2 PRODUCT PORTFOLIO 166
14.17.3 RECENT DEVELOPMENT 167
14.18 SARTORIUS AG 168
14.18.1 COMPANY SNAPSHOT 168
14.18.2 REVENUE ANALYSIS 168
14.18.3 PRODUCT PORTFOLIO 169
14.18.4 RECENT DEVELOPMENTS 169
14.19 SYSMEX CORPORATION 170
14.19.1 COMPANY SNAPSHOT 170
14.19.2 REVENUE ANALYSIS 170
14.19.3 PRODUCT PORTFOLIO 171
14.19.4 RECENT DEVELOPMENT 171
14.20 ZIFO RND SOLUTIONS 172
14.20.1 COMPANY SNAPSHOT 172
14.20.2 PRODUCT PORTFOLIO 172
14.20.3 RECENT DEVELOPMENTS 172
15 QUESTIONNAIRE 173
16 RELATED REPORTS 177

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.